Cargando…

Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle.

Radioimmunotherapy (RIT) is currently limited by toxicity to normal tissues as a result of prolonged circulating radioantibody in the blood. In this study, the use of a clearing antibody was investigated (second antibody) in an attempt to reduce blood background levels of [90Y]A5B7 immunoglobulin G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casey, J. L., King, D. J., Pedley, R. B., Boden, J. A., Boden, R., Chaplin, L. C., Dorning, M., Begent, R. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063187/ https://www.ncbi.nlm.nih.gov/pubmed/9823971

Ejemplares similares

Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
por: Marshall, D., et al.
Publicado: (1994)

Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
por: Marshall, D., et al.
Publicado: (1995)

Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.
por: Marshall, D., et al.
Publicado: (1996)

The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
por: Pedley, R. B., et al.
Publicado: (1994)

Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice.
por: Turner, A., et al.
Publicado: (1994)

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
por: Pedley, R. B., et al.
Publicado: (1993)

The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.
por: Pedley, R. B., et al.
Publicado: (1989)

Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry.
por: Pedley, R. B., et al.
Publicado: (1990)

Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study
por: Casey, J L, et al.
Publicado: (2002)

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
por: Casey, J. L., et al.
Publicado: (1996)

Versatile Macrocyclic Platform for the Complexation of [(nat)Y/(90)Y]Yttrium and Lanthanide Ions
por: Harriswangler, Charlene, et al.
Publicado: (2022)

Prolonged localisation of a monoclonal antibody against CEA in a human colon tumour xenograft.
por: Harwood, P. J., et al.
Publicado: (1985)

Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.
por: Delgado, C., et al.
Publicado: (1996)

Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
por: Rogers, G. T., et al.
Publicado: (1995)

The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.
por: Melton, R. G., et al.
Publicado: (1990)

The DOTA macrocyclic cavity in metallic radiopharmaceuticals: Mythology or reality?
por: Duatti, Adriano
Publicado: (2023)

Theranostic Imaging of Yttrium-90
por: Wright, Chadwick L., et al.
Publicado: (2015)

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments
por: Casey, J L, et al.
Publicado: (1999)

Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.
por: Boxer, G. M., et al.
Publicado: (1994)

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.
por: Ledermann, J. A., et al.
Publicado: (1988)

Trans-arterial hepatic radioembolisation of yttrium-90 microspheres
por: Murthy, R, et al.
Publicado: (2006)

Side Effects of Yttrium-90 Radioembolization
por: Riaz, Ahsun, et al.
Publicado: (2014)

Yttrium 90 Therapy: Is the Future Surgical?
por: Garlipp, Benjamin
Publicado: (2020)

Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material
por: Webley, S D, et al.
Publicado: (2001)

Preparation & in vitro evaluation of (90)Y-DOTA-rituximab
por: Kameswaran, Mythili, et al.
Publicado: (2016)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

Dose-dependent localisation and potential for therapy of F(ab')2 fragments against CEA studied in a human tumour xenograft model.
por: Rogers, G. T., et al.
Publicado: (1986)

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia
por: Vo, Phuong, et al.
Publicado: (2020)

Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
por: Keeling, A. A., et al.
Publicado: (1989)

Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials
por: Hosono, Makoto, et al.
Publicado: (2019)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

Intrahepatic flow diversion prior to segmental Yttrium-90 radioembolization for challenging tumor vasculature
por: Young, Lindsay B., et al.
Publicado: (2022)

Yttrium-90 Radioembolization: An Unusual Cause of Radiating Abdominal Pain
por: Estes, Derek J., et al.
Publicado: (2019)

Quantitative and Qualitative Assessment of Yttrium-90 PET/CT Imaging
por: Attarwala, Ali Asgar, et al.
Publicado: (2014)

In Vitro Characterization of (177)Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer
por: Mohajershojai, Tabassom, et al.
Publicado: (2022)

Yttrium-90 microsphere induced gastrointestinal tract ulceration
por: South, Christopher D, et al.
Publicado: (2008)

Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma
por: Lee, Victor Ho-Fun, et al.
Publicado: (2015)

Internal dosimetry for radioembolization therapy with Yttrium‐90 microspheres
por: Fallahpoor, Maryam, et al.
Publicado: (2017)

History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
por: Saini, Aman, et al.
Publicado: (2019)

Role of Yttrium-90 Radioembolization for Colorectal Hepatic Metastasis
por: Kim, Hyo-Cheol
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_909iquh7ahitornrjsk9lflctf